4//SEC Filing
OBALON THERAPEUTICS INC 4
Accession 0001209191-16-145725
$HINDCIK 0001427570operating
Filed
Oct 11, 8:00 PM ET
Accepted
Oct 12, 5:38 PM ET
Size
39.8 KB
Accession
0001209191-16-145725
Insider Transaction Report
Form 4
Stevenson Sharon
Director
Transactions
- Conversion
Series B Preferred Stock
2016-10-12−266,829→ 0 total(indirect: By Okapi Ventures, L.P.)→ Common Stock (266,829 underlying) - Conversion
Common Stock
2016-10-12+190,780→ 190,780 total(indirect: By Okapi Ventures, L.P.) - Conversion
Common Stock
2016-10-12+266,829→ 457,609 total(indirect: By Okapi Ventures, L.P.) - Conversion
Common Stock
2016-10-12+40,995→ 498,604 total(indirect: By Okapi Ventures, L.P.) - Conversion
Common Stock
2016-10-12+60,290→ 341,235 total(indirect: By Okapi Ventures II, L.P.) - Conversion
Series C Preferred Stock
2016-10-12−40,995→ 0 total(indirect: By Okapi Ventures, L.P.)→ Common Stock (40,995 underlying) - Conversion
Common Stock
2016-10-12+161,504→ 161,504 total(indirect: By Okapi Ventures II, L.P.) - Conversion
Common Stock
2016-10-12+47,629→ 546,233 total(indirect: By Okapi Ventures, L.P.) - Conversion
Common Stock
2016-10-12+119,441→ 280,945 total(indirect: By Okapi Ventures II, L.P.) - Conversion
Series A Preferred Stock
2016-10-12−143,677→ 0 total(indirect: By Okapi Ventures, L.P.)→ Common Stock (190,780 underlying) - Conversion
Series D Preferred Stock
2016-10-12−119,441→ 0 total(indirect: By Okapi Ventures II, L.P.)→ Common Stock (119,441 underlying) - Conversion
Series E Preferred Stock
2016-10-12−47,629→ 0 total(indirect: By Okapi Ventures, L.P.)→ Common Stock (47,629 underlying) - Conversion
Series E Preferred Stock
2016-10-12−60,290→ 0 total(indirect: By Okapi Ventures II, L.P.)→ Common Stock (60,290 underlying) - Conversion
Series C Preferred Stock
2016-10-12−161,504→ 0 total(indirect: By Okapi Ventures II, L.P.)→ Common Stock (161,504 underlying) - Conversion
Series C Preferred Stock Warrant (right to buy)
2016-10-12−4,037→ 0 total(indirect: By Okapi Ventures, L.P.)Exercise: $6.19Exp: 2019-02-24→ Series C Preferred Stock (4,037 underlying) - Conversion
Common Stock Warrant (right to buy)
2016-10-12+4,037→ 4,037 total(indirect: By Okapi Ventures, L.P.)Exercise: $6.19Exp: 2019-02-24→ Common Stock (4,037 underlying)
Footnotes (9)
- [F1]Each share of the issuer's Series A Preferred Stock automatically converted into 1.327844907 shares of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
- [F2]These securities are held of record by Okapi Ventures, L.P. ("OV"). Okapi Venture Partners, LLC ("OVLLC") is the general partner of OV. The reporting person is a managing director of OVLLC, and shares voting and investment power over the securities. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person is a beneficial owner of these securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
- [F3]Each share of the issuer's Series B Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
- [F4]Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
- [F5]These securities are held of record by Okapi Ventures II, L.P. ("OVII"). Okapi Venture Partners II, LLC ("OVIILLC") is the general partner of OVII. The reporting person is a managing director of OVIILLC, and shares voting and investment power over the securities. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person is a beneficial owner of these securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
- [F6]Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
- [F7]Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
- [F8]The warrant is exercisable at any time at the holder's election on a one-for-one basis. If not exercised prior to the closing of the IPO, the warrant will convert into a warrant to purchase shares of the issuer's Common Stock on a one-for-one basis.
- [F9]The warrant is exercisable at any time at the holder's election.
Documents
Issuer
OBALON THERAPEUTICS INC
CIK 0001427570
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001427570
Filing Metadata
- Form type
- 4
- Filed
- Oct 11, 8:00 PM ET
- Accepted
- Oct 12, 5:38 PM ET
- Size
- 39.8 KB